ESTRO 2022 - Abstract Book

S525

Abstract book

ESTRO 2022

Conclusion This national CED program prospectively evaluated SBRT implementation across Belgium. It shows that patients treated for OMD in the Belgian clinical practice were carefully selected. While variable, treatment characteristics and survival data conform to those previously reported in the literature. Together with data collection in ongoing clinical trials and other prospective cohorts such as OligoCare, these data allow to better understand and define the role of metastasis-directed radiotherapy in different OMD indications.

OC-0601 Incidence and outcomes of oligometastatic esophagogastric cancer: A multicenter cohort study

T. Kroese 1 , S. Christ 2 , M. Burger 1 , G. Buijs 1 , P. van Rossum 1 , C. Gutschow 3 , M. Hüllner 4 , U. Mühlematter 4 , R. van Hillegersberg 5 , M. Guckenberger 2 1 University Medical Center Utrecht, Radiation Oncology, Utrecht, The Netherlands; 2 University Hospital Zurich, Radiation Oncology, Zürich, Switzerland; 3 University Hospital Zurich, Surgery, Zürich, Switzerland; 4 University Hospital Zurich, Nuclear Medicine, Zürich, Switzerland; 5 University Medical Center Utrecht, Surgery, Utrecht, The Netherlands Purpose or Objective Patients with distant metastases from esophagogastric cancer have a poor prognosis with an overall survival (OS) of 4-11 months. This multicenter study assessed the incidence and outcomes of de-novo oligometastatic disease (OMD) in patients with esophagogastric cancer in two tertiary referral cancer centers in Europe.

Materials and Methods